GW Pharmaceuticals Ltd - Company Profile
Powered by
All the data and insights you need on GW Pharmaceuticals Ltd in one report.
- Save hours of research time and resources with
our up-to-date GW Pharmaceuticals Ltd Strategy Report
- Understand GW Pharmaceuticals Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
GW Pharmaceuticals Plc (GW Pharmaceuticals), a subsidiary of Jazz Pharmaceuticals, is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary plant-derived cannabinoid product platform. The company offers Sativex for the treatment of spasticity due to multiple sclerosis and Epidiolex for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome. It sells and distributes the product through strategic collaborations with other pharmaceutical companies. The company has subsidiaries in Australia, the US, England and Wales, and Guernsey. GW Pharmaceuticals is headquartered in Cambridge, England, the UK.
GW Pharmaceuticals Ltd premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Marketed | Savitex |
Sativex | Epidiolex |
Epidiolex/Epidyolex | |
XYZ | |
XYZ | |
XYZ |
Competitor Comparison
Key Parameters | GW Pharmaceuticals Ltd | Takeda Pharmaceutical Co Ltd | Evotec SE | Napp Pharmaceuticals Ltd | Oxford BioMedica Plc |
---|---|---|---|---|---|
Headquarters | United Kingdom | Japan | Germany | United Kingdom | United Kingdom |
City | Cambridge | Chuo-Ku | Hamburg | Cambridge | Oxford |
State/Province | England | Tokyo | Baden-Wurttemberg | England | England |
No. of Employees | - | 49,095 | 5,086 | 194 | 891 |
Entity Type | Private | Public | Public | Private | Public |
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Aislinn Jane Doody | Secretary | Senior Management | 2023 | - |
Nelly Alexandra | Assistant General Counsel; Director - Global ESG | Senior Management | 2023 | - |
David Spackman | Head - Marketing Europe and International | Senior Management | 2023 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward